On Dec. 21, 2020, CureVac announced that the first participant in a clinical Phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz were scheduled to be vaccinated on Dec. 22, 2020.

The study aimed to evaluate the safety and immunogenicity of CVnCoV administered as a two-dose schedule of 12 ﾵg. The trial follows an epidemiological, non-interventional study conducted with healthcare workers from the University Hospital in Mainz.